nature portfolio

Last updated by author(s): Jan 18, 2024

Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our <u>Editorial Policies</u> and the <u>Editorial Policy Checklist</u>.

| ~ | | | | |
|------------|-----|-----|----|--------|
| \ 1 | ta: | tic | ŤΙ | \sim |

| For | all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section. |
|-----|--|
| n/a | Confirmed |
| | The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement |
| X | A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly |
| | The statistical test(s) used AND whether they are one- or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section. |
| X | A description of all covariates tested |
| | A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons |
| | A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals) |
| | For null hypothesis testing, the test statistic (e.g. <i>F</i> , <i>t</i> , <i>r</i>) with confidence intervals, effect sizes, degrees of freedom and <i>P</i> value noted <i>Give P values as exact values whenever suitable.</i> |
| | For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings |
| X | For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes |
| | Estimates of effect sizes (e.g. Cohen's d , Pearson's r), indicating how they were calculated |
| | Our web collection on <u>statistics for biologists</u> contains articles on many of the points above. |
| | |

Software and code

Policy information about availability of computer code

Data collection

No software was used for data collection.

Data analysis

All analyses were performed using open source software. Code to run MR analyses can be found at MR-Base (https://mrcieu.github.io/ TwoSampleMR/). Code to run LDSC is available at https://github.com/bulik/ldsc. Code to run SMR is available at https:// yanglab.westlake.edu.cn/software/smr/#Overview. A tutorial for running Bayesian colocalization is available by Chris Wallace at https://cran.r-project.org/web/packages/coloc/vignettes/a02_data.html.

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio guidelines for submitting code & software for further information.

Data

Policy information about availability of data

All manuscripts must include a <u>data availability statement</u>. This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our policy

Provide your data availability statement here.

| Human rese | earch part | icipants | | | |
|--|--|--|--|--|--|
| Policy information about studies involving human research participants and Sex and Gender in Research. | | | | | |
| Reporting on sex | and gender | All analyses were done in populations containing both sexes. | | | |
| Population chara | acteristics | We used summary data. | | | |
| Recruitment | | NA, no participants were recruited. | | | |
| Ethics oversight | | All data used had been previously approved by ethical boards via their respective authors. | | | |
| Note that full informa | ation on the app | proval of the study protocol must also be provided in the manuscript. | | | |
| Field-spe | ecific re | eporting | | | |
| Please select the o | ne below that | is the best fit for your research. If you are not sure, read the appropriate sections before making your selection. | | | |
| X Life sciences | _ | Behavioural & social sciences | | | |
| For a reference copy of | the document with | h all sections, see <u>nature.com/documents/nr-reporting-summary-flat.pdf</u> | | | |
| Life sciences study design | | | | | |
| All studies must disclose on these points even when the disclosure is negative. | | | | | |
| Sample size | Varies. See Table 1. | | | | |
| Data exclusions | NA | | | | |
| Replication | We replicated the top findings from our metabolites screen on healthspan with a different instrument sources for APOB and LDL. | | | | |
| Randomization | We used Mendelian randomization, which is a quasi-randomization procedure. | | | | |
| Blinding | Blinding doesn't apply to Mendelian randomization with summary statistics. | | | | |
| | | | | | |
| Reporting for specific materials, systems and methods | | | | | |
| We require informati | ion from authors | s about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, o your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response. | | | |
| Materials & experimental systems Methods | | | | | |
| · | | n/a Involved in the study | | | |
| | | ChIP-seq Flow cytometry | | | |
| | | | | | |
| Animals and other organisms | | | | | |
| Clinical da | ta | | | | |
| Dual use r | Dual use research of concern | | | | |